Wound healing and treatment of fibrosis

• US 20020103112A1
• Filed: 09/26/2001
• Published: 08/01/2002
• Est. Priority Date: 12/04/1996
• Status: Abandoned Application

• Current Assignee: Mark W.J. Ferguson, Oʼkane, Sharon
• Original Assignee: Mark W.J. Ferguson, Oʼkane, Sharon
• Inventors: OʼKane, Sharon, Ferguson, Mark W.J.
• Application Number:
  US09/962,604
• Publication Number:
  US 20020103112A1
• Time in Patent Office: Days
• US Class Current: 514/2
• CPC Class Codes: A61K 38/1709 from mammals
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 27/02 Ophthalmic agents

Abstract

Compositions for use in the treatment of wounds and fibrosis comprising a therapeutically effective amount of a compound that modulates actin assembly and organization intracellularly and/or extracellularly and a pharmaceutically acceptable vehicle; such a compound promotes the rate of wound healing and also prevents or reduces fibrosis. A preferred compound is gelsolin.

Claims

1. The use of a compound that modulates actin assembly and organisation intracellularly and/or extracellularly for the manufacture of a medicament for the treatment of wounds or fibrosis.

2. The use according to claim 1 wherein the compound that modulates actin assembly and organisation severs actin filaments.

3. The use according to claim 2 wherein the compound is a selected from gelsolin, villin, CapG, adseverin, flightless-1, advillin and derivatives thereof

4. The use according to claim 3 wherein the compound is gelsolin or a derivative thereof.

5. The use according to any preceding claim for treating wounds to inhibit or prevent scar formation.

6. The use according to claim 5 for inhibiting or preventing scarring of the eye, nervous tissue or intestines.

7. The use according to claim 6 for inhibiting or preventing dermal scarring.

8. The use according to claim 6 for inhibiting or preventing scarring following a burn.

9. The use according to any one of claims 1-4 for treating wounds such that the rate of healing of wounds is increased.

10. The use according to claim 9 for treating acute wounds.

11. The use according to claim 10 wherein the acute wound is any one of a penetrative injury, a burn, nerve damage or a wound resulting from elective surgery.

12. The use according to claim 9 for treating chronic wounds.

13. The use according to claim 12 wherein the chronic wound is any one of diabetic, venous or decubitus ulcer or a wound of a generally healing compromised individual.

14. The use according to any one of claims 1-4 for preventing or reducing fibrosis.

15. The use according to claim 14 wherein the fibrosis is a fibrotic disorder

16. The use according to claim 15 wherein the fibrotic disorder is one of glomerulonephritis, cirrhosis of the liver, pulmonary fibrosis, adult respiratory distress syndrome or fibrocytic disease.

18. The composition according to claim 19 wherein the compound that modulates actin assembly and organisation severs actin filaments.

19. The composition according to claim 17 or 18 wherein the compound is selected from gelsolin, villin, CapG, adseverin, flightless-1, advillin and derivatives thereof.

20. The composition according to claim 19 wherein the compound is gelsolin or a derivative thereof.

17. A composition comprising a therapeutically elective amount of a compound that modulates actin assembly and organisation intracellularly and/or extracellularly and a pharmaceutically acceptable vehicle for the treatment of wounds or fibrosis.

21. A method of treating wounds or fibrosis comprising applying to the affected tissue a therapeutically effective amount of a compound which modulates actin assembly and organisation intracellularly and/or extracellularly.

22. A delivery system for use in a gene therapy technique, said delivery system comprising a DNA molecule encoding a protein which modulates actin assembly and organisation, said DNA molecule being capable of being transcribed to lead to the expression of said protein.

23. The delivery system according to claim 22 wherein the DNA molecule encodes one of gelsolin, villin, CapG, adseverin, flightless-1, advillin and derivatives thereof.

24. The use of a delivery system according to claims 22 or 23 for use in the manufacture of a medicament for use in the treatment of wounds or fibrosis.

25. A method of treating a wounds or fibrosis comprising administering to a patient in need of treatment a therapeutically effective amount of a delivery system according to claim 24 or 25.